First Manhattan’s Charles River Laboratories CRL Stock Holding History

First Manhattan’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,837	Closed	-$2.16M	–	760
2025 Q4	$2.16M	Buy	+10,837	New	+$1.97M	0.01%	332
2023 Q1	–	Sell	-103	Closed	-$22.4K	–	1559
2022 Q4	$22.4K	Buy	+103	New	+$22.5K	﹤0.01%	1086
2021 Q3	–	Sell	-20	Closed	-$7K	–	1595
2021 Q2	$7K	Buy	+20	New	+$6.68K	﹤0.01%	1328
2020 Q2	–	Sell	-97	Closed	-$12K	–	1384
2020 Q1	$12K	Buy	+97	New	+$14.5K	﹤0.01%	1098

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Manhattan's CRL Position: Q1 2026 in Review

First Manhattan sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 10,837 shares — an estimated $2.16M sold.

First Manhattan first reported a position in CRL in Q1 2020 and held it in 4 quarters. The position peaked at $2.16M in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

First Manhattan reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
First Manhattan sold 10,837 Charles River Laboratories shares in Q1 2026, an estimated $2.16M.
First Manhattan first reported a position in Charles River Laboratories in Q1 2020 and held it in 4 quarters.
First Manhattan's Charles River Laboratories position peaked at $2.16M in Q4 2025.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.